Ryan Cappelli
@Prosight Management, Lp
Latest period2024 - Q3ReportedManaged Assets$406.357MTotal holdings45
Assets growth rate21.46%Assets growth rate (2-Q avg)7.27%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Prosight Management, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 45 positions.
Assets under management
The assets under management (AUM) of Prosight Management, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 406.357M in assets, with a quarterly growth rate of 21.46% and a 2-quarter average growth rate of 7.27%. The portfolio is managed by Ryan Cappelli, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
MCKMckesson Corp
| 4.36% | $17.711M 35,822 shares@ $494.42 avg price | New Position |
JANXJanux Therapeutics Inc
| 2.3% | $9.313M 205,000 shares@ $45.43 avg price | New Position |
4642⤦Ishares Tr
| 1.58% | $6.406M↓ Put 29,000 shares@ $220.89 avg price | New Position |
HAEHaemonetics Corp Mass
| 1.29% | $5.225M 65,000 shares@ $80.38 avg price | New Position |
LIVNLivanova Plc
| 1.17% | $4.729M 90,000 shares@ $52.54 avg price | New Position |
1481⤦Cassava Sciences Inc
| 1.08% | $4.382M↓ Put 148,900 shares@ $29.43 avg price | New Position |
BPMCBlueprint Medicines Corp
| 1.08% | $4.357M 47,100 shares@ $92.5 avg price | New Position |
CTMXCytomx Therapeutics Inc
| 0.88% | $3.566M 3.022M shares@ $1.19 avg price | New Position |
SGHTSight Sciences Inc
| 0.83% | $3.347M 531,222 shares@ $6.31 avg price | New Position |
RCKTRocket Pharmaceuticals Inc
| 0.73% | $2.944M 159,369 shares@ $18.47 avg price | New Position |